Skip to main content

Find a Clinical Trial

Filter

Conditions treated
Services
Showing 41 - 50 out of 204
POETYK SjS-1
medical-cross
Sjogren's syndrome
user
All genders
person-wave 18+
world
Recruiting now
info
Department of Ophthalmology
medical-cross
Tufts Medical Center
Learn more
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
user
All genders
person-wave 18+
world
Recruiting now
info
Department of Medicine, Cancer Center
medical-cross
Tufts Medical Center
Learn more
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
medical-cross
Non-small cell lung cancer
user
All genders
person-wave 18+
world
Recruiting now
info
Department of Medicine, Division of Hematology/Oncology, Division of Thoracic Surgery
medical-cross
Tufts Medical Center
Learn more
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
medical-cross
Diffuse large B-cell lymphoma
user
All genders
person-wave 75+
world
Recruiting now
info
Department of Medicine, Division of Hematology/Oncology, Cancer Center
medical-cross
Tufts Medical Center
Learn more
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
medical-cross
Bladder cancer
user
All genders
person-wave 18+
world
Recruiting now
info
Department of Medicine, Cancer Center
medical-cross
Tufts Medical Center
Learn more
Perioperative versus adjuvant chemotherapy for pancreatic cancer
medical-cross
Pancreatic cancer
user
All genders
person-wave 18+
world
Recruiting now
info
Department of Medicine, Division of Hematology/Oncology, Cancer Center
medical-cross
Tufts Medical Center
Learn more
Jump back to top